Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Review Of Fertility Drug Use For Safety Signals To Use IMS Data

Executive Summary

FDA's Office of Drug Safety is conducting a nationwide analysis of the use of fertility drugs as a basis for an evaluation of post-marketing safety issues with fertility treatments

You may also be interested in...



FDA Expects To Act On New Drug Safety Cooperative Agreements By Sept. 30

FDA intends to sign new contracts that will provide the agency access to population-based data resources through its cooperative agreement program by Sept. 30

FDA Expects To Act On New Drug Safety Cooperative Agreements By Sept. 30

FDA intends to sign new contracts that will provide the agency access to population-based data resources through its cooperative agreement program by Sept. 30

Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return

Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor

Topics

UsernamePublicRestriction

Register

PS045994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel